Monte Rosa CSO Owen Wallace departs May 17 to become CEO at UK biotech; remains adviser

Monte Rosa Therapeutics, Inc.

Owen Wallace resigns as CSO effective May 17, 2024, to become CEO of a UK-based biotech company.
Departure is not due to any disagreement with Monte Rosa or its board; will continue as scientific adviser on SAB.
Drug discovery led by Sharon Towson (CTO), John Castle (CDIO), and Magnus Walter (SVP Drug Discovery).
Company expects no disruption to ongoing MGD programs or drug discovery efforts.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Owen Wallace

Chief Scientific Officer

GLUE · Monte Rosa Therapeutics, Inc.

Effective: 2024-05-17
Filed: May 2, 2024, 7:59 PM ET

On April 29, 2024, Owen Wallace, the Chief Scientific Officer of Monte Rosa Therapeutics, Inc. (the "Company"), resigned from the Company effective May 17, 2024 (the “Effective Date”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Owen Wallace resigned as Chief Scientific Officer at Monte Rosa Therapeutics, Inc..

Action: resigned
Role: Chief Scientific Officer

Exact text from the filing

On April 29, 2024, Owen Wallace, the Chief Scientific Officer of Monte Rosa Therapeutics, Inc. (the "Company"), resigned from the Company effective May 17, 2024 (the “Effective Date”).

View on SEC.gov

Monte Rosa Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-052055

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.